- Home
- FLUX vs INAB Comparison
FLUX vs INAB Comparison
Compare FLUX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLUX | INAB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 22.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLUX | INAB |
|---|---|---|
| Price | $1.05 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $6.00 |
| AVG Volume (30 Days) | ★ 126.5K | 65.0K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.97 | $0.12 |
| 52 Week High | $7.55 | $4.20 |
Technical Indicators
Market Signals| Indicator | FLUX | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 41.16 |
| Support Level | $1.04 | $1.17 |
| Resistance Level | $1.52 | $2.14 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 23.03 | 17.11 |
Price Performance
Historical ComparisonAbout FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.